Erdman Michael J, Riha Heidi, Bode Lauren, Chang Jason J, Jones G Morgan
Pharmacy Department, University of Florida Health, Jacksonville, FL, USA.
Pharmacy Department, Methodist University Hospital, Memphis, TN, USA.
Neurohospitalist. 2017 Jan;7(1):9-14. doi: 10.1177/1941874416665744. Epub 2016 Aug 29.
Continuous intravenous 3% hypertonic saline (HTS) infusions are commonly used for the management of cerebral edema following severe neurologic injuries. Despite widespread use, data regarding the incidence and predictors of nephrotoxicity are lacking. The purpose of this study was to describe the incidence and identify predictors of acute kidney injury (AKI) in neurocritical care patients administered continuous infusion HTS.
This was an institutional review board-approved, multicenter, retrospective cohort study of patients receiving HTS infusions at 2 academic medical centers. A univariate analysis and multivariable logistic regression were used to identify predictors of AKI. Data regarding AKI were evaluated during treatment with HTS and up to 24 hours after discontinuation.
A total of 329 patients were included in our analysis, with 54 (16%) developing AKI. Those who developed AKI experienced significantly longer stays in the intensive care unit (14.8 vs 11.5 days; = .006) and higher mortality (48.1% vs 21.9%; < .001). We identified past medical history of chronic kidney disease (odds ratio [OR]: 9.7, 95% confidence interval [CI]: 1.9-50.6; = .007), serum sodium greater than 155 mmol/L (OR: 4.1, 95% CI: 2.1-8.0; < .001), concomitant administration of piperacillin/tazobactam (OR: 3.9, 95% CI: 1.7-9.3; = .002), male gender (OR: 3.2, 95% CI: 1.5-6.6; = .002), and African American race (OR: 2.6, 95% CI: 1.3-5.2; = .007) as independent predictors of AKI.
Acute kidney injury is relatively common in patients receiving continuous HTS and may significantly impact clinical outcomes.
持续静脉输注3%高渗盐水(HTS)常用于治疗严重神经损伤后的脑水肿。尽管其应用广泛,但关于肾毒性的发生率及预测因素的数据仍很缺乏。本研究旨在描述接受持续输注HTS的神经重症患者急性肾损伤(AKI)的发生率,并确定其预测因素。
这是一项经机构审查委员会批准的多中心回顾性队列研究,研究对象为在2家学术医疗中心接受HTS输注的患者。采用单因素分析和多变量逻辑回归来确定AKI的预测因素。在HTS治疗期间及停药后24小时内评估有关AKI的数据。
我们的分析共纳入329例患者,其中54例(16%)发生AKI。发生AKI的患者在重症监护病房的住院时间显著更长(14.8天对11.5天;P = 0.006),死亡率更高(48.1%对21.9%;P < 0.001)。我们确定慢性肾脏病既往病史(比值比[OR]:9.7,95%置信区间[CI]:1.9 - 50.6;P = 0.007)、血清钠大于155 mmol/L(OR:4.1,95% CI:2.1 - 8.0;P < 0.001)、同时使用哌拉西林/他唑巴坦(OR:3.9,95% CI:1.7 - 9.3;P = 0.002)、男性(OR:3.2,95% CI:1.5 - 6.6;P = 0.002)和非裔美国人种族(OR:2.6,95% CI:1.3 - 5.2;P = 0.007)为AKI的独立预测因素。
接受持续HTS治疗的患者中急性肾损伤相对常见,且可能显著影响临床结局。